Trial reportPediatric research2025
Interventional impact of liposomal iron on iron-deficient children developmental outcome: randomized, double-blind, placebo-controlled trial.
Trial report in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Liposomal iron dramatic effect on chronic kidney disease pediatric anemia: a randomized clinical trial.Pediatric research · 2026Trial
- Article
- Pediatric Oral Iron Therapy: Choosing the Right Product for Your Patient.Hematology reports · 2026Review
- Iron Therapy in Pediatric Iron Deficiency and Iron-Deficiency Anemia: Efficacy, Safety, and Formulation-Specific Trade-Offs-A Narrative Review.Hematology reports · 2026Review
- Iron deficiency beyond anemia: implication for neurodevelopment and the potential of liposomal iron in children. A commentary.Pediatric research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron deficiency (ID) in children, especially those under five years, has a well-recognized negative impact on development and growth. However, the potential for reversibility with iron supplementation remains debatable. Therefore, we aimed in this double-blind placebo-controlled clinical trial to investigate the effect of the novel iron preparation, Liposomal Iron (LI), on the development and growth of iron-deficient children.
methodsFor iron deficiency anemia (IDA) and non-anemic iron deficiency (NAID), 433 children aged 6 to 59 months underwent screening. The NAID group was divided into two groups: one group received a placebo, while the interventional group received liposomal iron for four months, as in the IDA group. Then, compared to baseline, efficacy, development, and growth were reevaluated.
resultsThe NAID interventional group showed significant improvement in developmental total scores compared to the NAID placebo group with a mean difference of +29.57 versus +0.96 (P < 0.001). Furthermore, the final score was notably superior in the NAID interventional group 181.5, compared to the IDA group, 175.0 (P < 0.001).
conclusionsLiposomal iron showed, in addition to good efficacy and tolerability, a favorable impact on the development and growth of iron-deficient children. However, the best results were obtained from early management prior to the onset of anemia (NAID). IMPACT: NAID, though common, is still underappreciated, and evidence about the benefits of giving iron to children before IDA progression is limited. The Ages and Stages Questionnaires is a reliable screening tool for development during the critical first five years of life. Through an interventional clinical trial, LI demonstrated an effective and tolerable alternative for ID treatment, while overcoming the usual adverse effects of conventional iron therapies. Growth and developmental outcomes improved significantly with early detection and treatment of ID with LI during the NAID stage than when the supplement was used after anemia emergence. Conversely, children with NAID who received a placebo showed further deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.